Regarding the recent Comment/Guest Expert, “Higher employee cost-sharing could undermine job-based coverage system”, the Commonwealth Fund's Dr. David Blumenthal addressed many salient facts and issues relating to employer-based health insurance in his editorial.
Regarding the article “Bioethicists say patient-satisfaction surveys could lead to bad medicine”, this is a great example of unintended consequences.
Regarding the recent feature “Physician quality pay not paying off”, several reviews have shown no improvement in population health measures or cost savings from pay-for-performance or pay-for-quality.
Regarding coverage of the 50th anniversary of Medicare and Medicaid, in 1979 as an American Hospital Association/Blue Cross and Blue Shield Association fellow, I had the privilege of meeting Wilbur Cohen, the architect of Medicare and Medicaid, and the first secretary of the Department of Health,...
I want to applaud Modern Healthcare for the May 18 cover story on assisted suicide/hospice. It's a great topic, and as a family member of multiple hospice patients and executive director of Pathways Hospice in Ohio, I know that education on this subject is vital.
Regarding the article “Getting the data stream flowing: Hospitals want monitoring devices and EHRs to communicate”, entering vitals such as blood pressure, respiration rate and oxygen saturation from electronic monitors directly into the electronic health record saves time and...
Regarding the recent article “Healthcare spending rises 5.5% while rest of economy sputters”, I wonder if the rise in hospital costs could be related to the rapid growth of high-deductible health plans.
While not every innovation tested by the CMS is going to work, the evaluation should always be fair and give us insights into how to improve in the future.
Regarding the April 20 Q&A, “Healthcare should emulate banks on IT interoperability”, I spent 25 years as a chief information officer in the financial services industry, and I agree with the comment about technology interoperability.
Thanks for bringing the 340B drug discount program to the forefront with the article “Federal watchdogs seek better oversight of 340B drug discounts.”
The recent commentary on the price of cancer medicines, “Strong action needed to curb cancer drug prices,” ignores the competitive biopharmaceutical market that exists in the U.S., which keeps a check on spending growth while spurring the development of innovative new therapies for...
Regarding the recent guest commentary “Preventing readmissions requires engaging care team, employing technology,” (ModernHealthcare.com, March 30), data analytics can play a part in this as well.